Tributary Capital Management LLC Increases Stake in Enovis Corporation (NYSE:ENOV)

Tributary Capital Management LLC increased its holdings in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 8.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 611,525 shares of the company's stock after buying an additional 45,436 shares during the period. Enovis accounts for about 2.0% of Tributary Capital Management LLC's investment portfolio, making the stock its 9th biggest holding. Tributary Capital Management LLC owned approximately 1.07% of Enovis worth $23,366,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ENOV. Quadrant Capital Group LLC boosted its holdings in shares of Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock valued at $30,000 after buying an additional 239 shares during the period. California State Teachers Retirement System boosted its holdings in Enovis by 0.7% during the fourth quarter. California State Teachers Retirement System now owns 52,236 shares of the company's stock worth $2,292,000 after purchasing an additional 350 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Enovis by 4.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 10,737 shares of the company's stock worth $471,000 after purchasing an additional 458 shares during the last quarter. Xponance Inc. boosted its holdings in Enovis by 7.8% during the fourth quarter. Xponance Inc. now owns 6,380 shares of the company's stock worth $280,000 after purchasing an additional 462 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in Enovis by 266.7% during the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after purchasing an additional 536 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Canaccord Genuity Group dropped their price target on shares of Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Evercore ISI lowered their price target on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Needham & Company LLC lowered their price target on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, JMP Securities lowered their price target on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Enovis presently has an average rating of "Moderate Buy" and a consensus price target of $55.60.

Enovis Trading Down 14.8%

Shares of NYSE:ENOV traded down $4.57 during mid-day trading on Friday, hitting $26.29. The company had a trading volume of 3,974,842 shares, compared to its average volume of 932,407. The firm has a fifty day moving average price of $32.61 and a 200 day moving average price of $37.10. The company has a market capitalization of $1.50 billion, a PE ratio of -1.88 and a beta of 1.70. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.55 and a quick ratio of 1.32. Enovis Corporation has a one year low of $26.00 and a one year high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. The firm had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. Enovis had a negative net margin of 37.65% and a positive return on equity of 5.99%. The business's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.50 EPS. As a group, research analysts forecast that Enovis Corporation will post 2.79 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.